Eli Lilly (incl. Loxo)

Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer.

Selpercatinib is a selective RET inhibitor approved for any tumour with a RET fusion, with a further label update in July 2026.

Tersolisib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.

Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.

Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.

Olaratumab was approved in 2016 with doxorubicin for soft tissue sarcoma after a small trial suggested it added almost a year of life, but the large confirmatory trial found no benefit and it was withdrawn in 2019, a warning case for accelerated approvals.

Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer.

Pemetrexed is the chemotherapy that, with a platinum drug, became the first approved treatment for mesothelioma in 2004, and is still the backbone today.

A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.

Vinblastine is the vinca alkaloid in ABVD, the standard Hodgkin lymphoma regimen, and was formerly in the cisplatin combinations that first cured testicular cancer.

Vindesine is a vinca alkaloid, a semi-synthetic relative of vinblastine, used in Europe and elsewhere for acute lymphoblastic leukaemia and some solid tumours; it was never marketed in the United States.

Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head and neck cancer; RAS-mutant tumours gain nothing and may be harmed, so RAS testing comes first.

A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.

Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation.

Nabilone is a synthetic cannabinoid capsule approved in 1985 for chemotherapy-induced nausea and vomiting that standard drugs cannot control; like dronabinol it is a later-line option because of its effects on mood and balance.

Necitumumab (Portrazza) is an antibody added to gemcitabine and cisplatin as first treatment for squamous non-small cell lung cancer that has spread; the benefit is modest and it is little used.

Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer.

Pegilodecakin, a long-acting interleukin-10 meant to expand tumour-killing T cells, added nothing to FOLFOX in the phase 3 SEQUOIA trial of second-line pancreatic cancer, and Eli Lilly dropped it.

A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025.

Raloxifene (Evista) is an osteoporosis tablet that also lowers the chance of developing invasive breast cancer in postmenopausal women at higher risk, with fewer womb-cancer problems than tamoxifen.

An antibody that blocks the VEGF receptor, approved in liver cancer only for patients with a high AFP blood level, the first biomarker-selected HCC drug.

Sintilimab is Innovent's PD-1 antibody, approved in China since 2018 for Hodgkin lymphoma and then, on the ORIENT trials, for first-line lung, liver, oesophageal and stomach cancer. In 2022 the FDA rejected its lung cancer application because a China-only trial against chemotherapy did not fit US practice, defining the agency's stance on single-country data.